Sirtuin activators and inhibitors

BioFactors

Volumn 38, Issue 5, 2012, Pages 349-359

  Villalba, José M ^a   Alcaín, Francisco J ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Resveratrol; Sirtuin activators; Sirtuin inhibitors; Sirtuins; SRT1720

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; AGK 2; CAMBINOL; CAMPTOTHECIN; CISPLATIN; ENZYME ACTIVATOR; ENZYME INHIBITOR; IMIDAZO[1,2 BETA]THIAZOLE DERIVATIVE; LONGEVINEX; NICOTINAMIDE; OXAZOLO[4,5 BETA]PYRIDINE DERIVATIVE; PLACEBO; PREDNISONE; RESVERATROL; RESVIDA; SALERMIDE; SIRTINOL; SIRTUIN; SIRTUIN ACTIVATOR; SIRTUIN INHIBITOR; SPLITOMICIN; SRT 1460; SRT 1720; SRT 2104; SRT 2183; SRT 2379; SURAMIN; TENOVIN; UNCLASSIFIED DRUG;

AGING; BURKITT LYMPHOMA; CANCER THERAPY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL LOSS; COLITIS; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FRAGILE X SYNDROME; HEART FUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INSULIN RESISTANCE; LEISHMANIASIS; METABOLIC DISORDER; NEOPLASM; NERVE CELL; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARASITOSIS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TRYPANOSOMIASIS;

ANTIOXIDANTS; ENZYME ACTIVATORS; ENZYME INHIBITORS; FRAGILE X SYNDROME; HIV; HIV INFECTIONS; HUMANS; NAPHTHOLS; NEOPLASMS; NEURODEGENERATIVE DISEASES; OBESITY; SIRTUINS; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867702707     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1032     Document Type: Review

References (111)

1. Tissenbaum H. A. and Guarente, L. (2001) Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410, 227-230.
2. Rogina, B. and Helfand, S. L. (2004) Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. USA 101, 15998-16003.
3. Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., et al. (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase, Science 305, 390-392.
4. Burnett, C., Valentini, S., Cabreiro, F., Goss, M., Somogyvári, M., et al. (2011) Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila, Nature, 477, 482-485.
5. Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., et al. (2000) The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. USA 97, 5807-5811.
6. Brittain, W. H. and Ottow, E. (2007) Recent advances in the medicinal chemistry of histone deacetylase inhibitors. Ann. Rep. Med. Chem. 42, 337-348.
7. Michan, S. and Sinclair, D. (2007) Sirtuins in mammals: insights into their biological function. Biochem. J. 404, 1-13.
8. Vaziri, H., Dessain, S. K., Ng Eaton, E., Imai, S. I., Frye, R. A., et al. (2001) hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159.
9. North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., Verdin, E. (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell. 11, 437-444.
10. North, B. J. and Verdin, E. (2007) Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One 2, e784.
11. Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., and Horio, Y. (2007) Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J. Biol. Chem. 282, 6823-6832.
12. Ford, E., Voit, R., Liszt, G., Magin, C., Grummt, I., et al. (2006) Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription, Genes. Dev. 20, 1075-1080.
13. Mahlknecht, U., Ho, A. D., and Voelter-Mahlknecht, S. (2006) Chromosomal organization and fluorescence in situ hybridization of the human Sirtuin 6 gene, Int. J. Oncol. 28, 447-456.
14. Silva, J. P. and Wahlestedt, C. (2010) Role of Sirtuin 1 in metabolic regulation. Drug Discov. Today 15, 781-791.
15. Nemoto, S., Fergusson, M. M., and Finkel, T. (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem. 280, 16456-16460.
16. Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434, 113-118.
17. Ramadori, G., Lee, C. E., Bookout, A. L., Lee, S., Williams, K. W., et al. (2008) Brain SIRT1: anatomical distribution and regulation by energy availability. J. Neurosci. 28, 9989-9996.
18. Ramadori, G., Fujikawa, T., Fukuda, M., Anderson, J., Morgan, D. A., et al. (2010) SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity. Cell Metab. 12, 78-87.
19. Clark, S. J., Falchi, M., Olsson, B., Jacobson, P., Cauchi, S., et al. (2012) Association of sirtuin 1 (SIRT1) gene SNPs and transcript expression levels with severe obesity. Obesity (Silver Spring) 20, 178-185.
20. Flachsbart, F., Croucher, P. J., Nikolaus, S., Hampe, J., Cordes, C., et al. (2006) Sirtuin 1 (SIRT1) sequence variation is not associated with exceptional human longevity. Exp. Gerontol. 41, 98-102.
21. Kabra, N., Li, Z., Chen, L., Li, B., Zhang, X., et al. (2009) SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J. Biol. Chem. 284, 18210-18217.
22. Alcain, F. J. and Villalba, J. M. (2009) Sirtuin inhibitors. Expert Opin. Ther. Pat. 19, 283-294.
23. Audrito, V., Vaisitti, T., Rossi, D., Gottardi, D., D'Arena, G., et al. (2011) Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 71, 4473-4483.
24. Wang, R. H., Sengupta, K., Li, C., Kim, H. S., Cao, L., et al. (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 14, 312-323.
25. Li, W., Zhang, B., Tang, J., Cao, Q., Wu, Y., et al. (2007) Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J. Neurosci. 27, 2606-2616.
26. Dryden, S. C., Nahhas, F. A., Nowak, J. E., Goustin, A. S., and Tainsky, M. A. (2003) Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell. Biol. 23, 3173-3185.
27. Hiratsuka, M., Inoue, T., Toda, T., Kimura, N., Shirayoshi, Y., et al. (2003) Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem. Biophys. Res. Commun. 309, 558-566.
28. Kim, H. S., Vassilopoulos, A., Wang, R. H., Lahusen, T., Xiao, Z., et al. (2011) SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20, 487-499.
29. Verdin, E., Hirschey, M. D., Finley, L. W., and Haigis, M. C. (2010) Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem. Sci. 35, 669-675.
30. Bellizzi, D., Rose, G., Cavalcante, P., Covello, G., Dato, S., et al. (2005) A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 85, 258-263.
31. Zhong, L. and Mostoslavsky, R. (2011) Fine tuning our cellular factories: sirtuins in mitochondrial biology. Cell Metab. 13, 621-626.
32. Gertz, M. and Steegborn, C. (2010) Function and regulation of the mitochondrial sirtuin isoform Sirt5 in Mammalia. Biochim. Biophys. Acta. 1804, 1658-1665.
33. Mao, Z., Hine, C., Tian, X., Van Meter, M., Au, M., et al. (2011) SIRT6 promotes DNA repair under stress by activating PARP1. Science 332, 1443-1446.
34. Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., et al. (2006) Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124, 315-329.
35. Van Meter, M., Mao, Z., Gorbunova, V., and Seluanov, A. (2011) SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 10, 3153-3158.
36. Vakhrusheva, O., Braeuer, D., Liu, Z., Braun, T., and Bober, E. (2008) Sirt7-dependent inhibition of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. J. Physiol. Pharmacol. 59, 201-212.
37. Vakhrusheva, O., Smolka, C., Gajawada, P., Kostin, S., Boettger, T., et al. (2008) Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ. Res. 102, 703-710.
38. Tsai, Y. C., Greco, T. M., Boonmee, A., Miteva, Y., and Cristea, I. M. (2012) Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol. Cell. Proteomics 11, M111 015156.
39. Alcain, F. J., Minor, R. K., Villalba, J. M., and de Cabo, R. (2010) In The Future of Aging. Small Molecule Modulators of Sirtuin Activity. (Fahy, G. M., West, M. D., Harris, S. B., eds.). pp. 331-356, Springer, Heidelberg, London, New York.
40. Lin, S. J., Defossez, P. A., and Guarente, L. (2000) Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289, 2126-2128.
41. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196.
42. Wood, J. G., Rogina, B., Lavu, S., Howitz, K., and Helfand, S. L. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430, 686-689.
43. Barger, J. L., Kayo, T., Pugh, T. D., Prolla, T. A., and Weindruch, R. (2008) Short-term consumption of a resveratrol-containing nutraceutical mixture mimics gene expression of long-term caloric restriction in mouse heart. Exp. Gerontol. 43, 859-866.
44. Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L., Price, N. L., et al. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8, 157-168.
45. Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., et al. (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281, 21745-21754.
46. Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., et al. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis, EMBO J. 26, 3169-3179.
47. Alcain, F. J. and Villalba, J. M. (2009) Sirtuin activators. Exp. Opin. Ther. Pat. 19, 403-414.
48. Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., et al. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6, e19881.
49. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342.
50. Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., et al. (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14, 612-622.
51. Wong, R. H., Howe, P. R., Buckley, J. D., Coates, A. M., Kunz, I., et al. (2011) Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 21, 851-856.
52. Fujitaka, K., Otani, H., Jo, F., Jo, H., Nomura, E., et al. (2011) Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr. Res. 31, 842-847.
53. Smith, J. J., Kenney, R. D., Gagne, D. J., Frushour, B. P., Ladd, W., et al. (2009) Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst. Biol. 3, 31.
54. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., et al. (2011) Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila) 4, 1419-1425.
55. Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716.
56. Feige, J. N., Lagouge, M., Canto, C., Strehle, A., Houten, S. M., et al. (2008) Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 8, 347-358.
57. Funk, J. A., Odejinmi, S., and Schnellmann, R. G. (2010) SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J. Pharmacol. Exp. Ther. 333, 593-601.
58. Yamazaki, Y., Usui, I., Kanatani, Y., Matsuya, Y., Tsuneyama, K., et al. (2009) Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am. J. Physiol. Endocrinol. Metab. 297, E 1179-1186.
59. Minor, R. K., Baur, J. A., Gomes, A. P., Ward, T. M., Csiszar, A., et al. (2011) SRT1720 suppresses apoptosis and restores a more normal gene expression profile indicative of reduced inflammation in the livers of mice fed a high-fat diet. Scientific Reports 1, 10.1038/srep00070.
60. Chauhan, D., Bandi, M., Singh, A. V., Ray, A., Raje, N., et al. (2011) Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br. J. Haematol. 155, 588-598.
61. Bemis, J. E., Vu, C. B., Xie, R., Nunes, J. J., Ng, P. Y., et al. (2009) Discovery of oxazolo[4, 5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg. Med. Chem. Lett. 19, 2350-2353.
62. Vu, C. B., Bemis, J. E., Disch, J. S., Ng, P. Y., Nunes, J. J., et al. (2009) Discovery of imidazo[1, 2-b]thiazole derivatives as novel SIRT1 activators. J. Med. Chem. 52, 1275-1283.
63. Ellis, D. J. G. J. L., Suri, V., Cermak, J. M., Lyng, G. D., Guarente, L. P., and Vlasuk, G. P. (2011) SRT2104, a novel and selective small molecule SIRT1 activator, inhibits DSS-induced colitis in a SIRT1-dependent manner, 10th World Congress on Inflammation, Paris.
64. Van Der Meer, A., Scicluna, B., Lin, J., Jacobson, E., Vlasuk, G. P., et al. (2011) The first demonstration of clinical activity by a small molecule sirt1 activator: srt2104 reduces cytokine release and coagulation activation in a human endotoxemia model., 10th World Congress on Inflammation, Paris.
65. Nayagam, V. M., Wang, X., Tan, Y. C., Poulsen, A., Goh, K. C., et al. (2006) SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen. 11, 959-967.
66. Mai, A., Valente, S., Meade, S., Carafa, V., Tardugno, M., et al. (2009) Study of 1, 4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J. Med. Chem. 52, 5496-5504.
67. Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S. C., et al. (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74, 619-624.
68. Borra, M. T., Smith, B. C., and Denu, J. M. (2005) Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195.
69. Huber, J. L., Mcburney, M. W., Distefano, P. S., and Mcdonagh, T. (2010) SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med. Chem. 2, 1751-1759.
70. Kaeberlein, M., Mcdonagh, T., Heltweg, B., Hixon, J., Westman, E. A., et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038-17045.
71. Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D., Flynn, D., et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 285, 8340-8351.
72. Milne, J. C. and Denu, J. M. (2008) The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 12, 11-17.
73. Walle, T., Hsieh, F., Delegge, M. H., Oatis, J. E., Jr, and Walle, U. K. (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377-1382.
74. Dai, H., Kustigian, L., Carney, D., Case, A., Considine, T., et al. (2010) SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem. 285, 32695-32703.
75. Canto, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458, 1056-1060.
76. Canto, C., Jiang, L. Q., Deshmukh, A. S., Mataki, C., Coste, A., et al. (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 11, 213-219.
77. Park, S. J., Ahmad, F., Philp, A., Baar, K., Williams, T., et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421-433.
78. Sauve, A. A. and Schramm, V. L. (2003) Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 42, 9249-9256.
79. Giammona, L. M., Panuganti, S., Kemper, J. M., Apostolidis, P. A., Lindsey, S., et al. (2009) Mechanistic studies on the effects of nicotinamide on megakaryocytic polyploidization and the roles of NAD+ levels and SIRT inhibition. Exp. Hematol. 37, 1340-1352 e1343.
80. Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519.
81. Vergnes, B., Vanhille, L., Ouaissi, A., and Sereno, D. (2005) Stage-specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase. Acta Trop. 94, 107-115.
82. Pagans, S., Pedal, A., North, B. J., Kaehlcke, K., Marshall, B. L., et al. (2005) SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 3, e41.
83. Pereira, C. V., Lebiedzinska, M., Wieckowski, M. R., and Oliveira, P. J. (2012) Regulation and protection of mitochondrial physiology by sirtuins. Mitochondrion 12, 66-76.
84. Chen, L. (2011) Medicinal chemistry of sirtuin inhibitors. Curr. Med. Chem. 18, 1936-1946.
85. Mahajan, S. S., Leko, V., Simon, J. A., and Bedalov, A. (2011) In Handbook of Experimental Pharmacology. Histone Deacetylases: The Biology and Clinical Implication (Yao, T.-P., and Seto, E. (eds.), Springer, Heidelberg, London, New York. pp. 241-255.
86. Bedalov, A., Gatbonton, T., Irvine, W. P., Gottschling, D. E., and Simon, J. A. (2001) Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA 98, 15113-15118.
87. Neugebauer, R. C., Uchiechowska, U., Meier, R., Hruby, H., Valkov, V., et al. (2008) Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J. Med. Chem. 51, 1203-1213.
88. Biacsi, R., Kumari, D., and Usdin, K. (2008) SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet. 4, e1000017.
89. Grozinger, C. M., Chao, E. D., Blackwell, H. E., Moazed, D., and Schreiber, S. L. (2001) Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276, 38837-38843.
90. Mai, A., Massa, S., Lavu, S., Pezzi, R., Simeoni, S., et al. (2005) Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 48, 7789-7795.
91. Ota, H., Tokunaga, E., Chang, K., Hikasa, M., Iijima, K., et al. (2006) Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25, 176-185.
92. Jin, K. L., Park, J. Y., Noh, E. J., Hoe, K. L., Lee, J. H., et al. (2010) The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J. Gynecol. Oncol. 21, 262-268.
93. Kojima, K., Ohhashi, R., Fujita, Y., Hamada, N., Akao, Y., et al. (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 373, 423-428.
94. Peck, B., Chen, C. Y., Ho, K. K., Di Fruscia, P., Myatt, S. S., et al. (2010) SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther. 9, 844-855.
95. Alhazzazi, T. Y., Kamarajan, P., Joo, N., Huang, J. Y., Verdin, E., et al. (2011) Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 117, 1670-1678.
96. Catoire, H., Pasco, M. Y., Abu-Baker, A., Holbert, S., Tourette, C., et al. (2008) Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum. Mol. Genet. 17, 2108-2117.
97. Pasco, M. Y., Rotili, D., Altucci, L., Farina, F., Rouleau, G. A., et al. (2010) Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues. J. Med. Chem. 53, 1407-1411.
98. Orecchia, A., Scarponi, C., Di Felice, F., Cesarini, E., Avitabile, S., et al. (2011) Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. PLoS One 6, e24307.
99. He, X., Nie, H., Hong, Y., Sheng, C., Xia, W., et al. (2012) SIRT2 activity is required for the survival of C6 glioma cells. Biochem. Biophys. Res. Commun. 417, 468-472.
100. Nie, H., Chen, H., Han, J., Hong, Y., Ma, Y., et al. (2011) Silencing of SIRT2 induces cell death and a decrease in the intracellular ATP level of PC12 cells. Int. J. Physiol. Pathophysiol. Pharmacol. 3, 65-70.
101. Luthi-Carter, R., Taylor, D. M., Pallos, J., Lambert, E., Amore, A., et al. (2010) SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. USA 107, 7927-7932.
102. Heltweg, B., Gatbonton, T., Schuler, A. D., Posakony, J., Li, H., et al. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66, 4368-4377.
103. Medda, F., Russell, R. J., Higgins, M., Mccarthy, A. R., Campbell, J., et al. (2009) Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J. Med. Chem. 52, 2673-2682.
104. Schuetz, A., Min, J., Antoshenko, T., Wang, C. L., Allali-Hassani, A., et al. (2007) Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 15, 377-389.
105. Trapp, J., Meier, R., Hongwiset, D., Kassack, M. U., Sippl, W., et al. (2007) Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem 2, 1419-1431.
106. Perabo, F. G. and Muller, S. C. (2005) New agents in intravesical chemotherapy of superficial bladder cancer. Scand. J. Urol. Nephrol. 39, 108-116.
107. Lain, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., et al. (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13, 454-463.
108. Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., et al. (2012) Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119, 1904-1914.
109. McCarthy, A. R., Pirrie, L., Hollick, J. J., Ronseaux, S., Campbell, J., et al. (2012) Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorg. Med. Chem. 20, 1779-1793.
110. Lara, E., Mai, A., Calvanese, V., Altucci, L., Lopez-Nieva, P., et al. (2009) Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28, 781-791.
111. Liu, G., Su, L., Hao, X., Zhong, N., Zhong, D., et al. (2011) Salermide upregulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J. Cell. Mol. Med. doi: 10.1111/j.1582-4934.2011.01401.x